| pubmed-article:16763786 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16763786 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:16763786 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:16763786 | lifeskim:mentions | umls-concept:C0146224 | lld:lifeskim |
| pubmed-article:16763786 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:16763786 | lifeskim:mentions | umls-concept:C1522690 | lld:lifeskim |
| pubmed-article:16763786 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:16763786 | lifeskim:mentions | umls-concept:C0701183 | lld:lifeskim |
| pubmed-article:16763786 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:16763786 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:16763786 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:16763786 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:16763786 | pubmed:dateCreated | 2006-6-9 | lld:pubmed |
| pubmed-article:16763786 | pubmed:abstractText | Aims of this study were to determine the toxicity profile and the recommended dose of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies. Caelyx: 35 (DLI) or 40 (DLII) mg/m2/d1 was followed by 0.5 mg/m2/d topotecan daily for 5 days, every 4 weeks. Twenty-three patients received a total of 82 cycles. At DLII, 2/6 patients experienced dose-limiting toxicity consisting of grade 4 neutropenia lasting for more than 7 days and febrile neutropenia. At DLI, 4/18 and 2/18 patients presented febrile neutropenia and grade 4 sustained neutropenia, respectively. Non-hematological toxicities were mild to moderate. One patient with ovarian cancer presented a complete response. The hematological toxicity was a dose limiting factor that led to the recommended dose of 35 mg/m2 Caelyx on day 1 with 0.5 mg/m2/d topotecan on days 1-5. This study results suggest that alternative schedules of this combination are required. | lld:pubmed |
| pubmed-article:16763786 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16763786 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16763786 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16763786 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16763786 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16763786 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16763786 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16763786 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:16763786 | pubmed:issn | 0167-6997 | lld:pubmed |
| pubmed-article:16763786 | pubmed:author | pubmed-author:FaivreSandrin... | lld:pubmed |
| pubmed-article:16763786 | pubmed:author | pubmed-author:PautierPatric... | lld:pubmed |
| pubmed-article:16763786 | pubmed:author | pubmed-author:RaymondEricE | lld:pubmed |
| pubmed-article:16763786 | pubmed:author | pubmed-author:ArmandJean-Pi... | lld:pubmed |
| pubmed-article:16763786 | pubmed:author | pubmed-author:LhomméCatheri... | lld:pubmed |
| pubmed-article:16763786 | pubmed:author | pubmed-author:DjazouliKamel... | lld:pubmed |
| pubmed-article:16763786 | pubmed:author | pubmed-author:DjafariLatifa... | lld:pubmed |
| pubmed-article:16763786 | pubmed:author | pubmed-author:LozahicStépha... | lld:pubmed |
| pubmed-article:16763786 | pubmed:author | pubmed-author:GhesquièresHe... | lld:pubmed |
| pubmed-article:16763786 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16763786 | pubmed:volume | 24 | lld:pubmed |
| pubmed-article:16763786 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16763786 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16763786 | pubmed:pagination | 413-21 | lld:pubmed |
| pubmed-article:16763786 | pubmed:meshHeading | pubmed-meshheading:16763786... | lld:pubmed |
| pubmed-article:16763786 | pubmed:meshHeading | pubmed-meshheading:16763786... | lld:pubmed |
| pubmed-article:16763786 | pubmed:meshHeading | pubmed-meshheading:16763786... | lld:pubmed |
| pubmed-article:16763786 | pubmed:meshHeading | pubmed-meshheading:16763786... | lld:pubmed |
| pubmed-article:16763786 | pubmed:meshHeading | pubmed-meshheading:16763786... | lld:pubmed |
| pubmed-article:16763786 | pubmed:meshHeading | pubmed-meshheading:16763786... | lld:pubmed |
| pubmed-article:16763786 | pubmed:meshHeading | pubmed-meshheading:16763786... | lld:pubmed |
| pubmed-article:16763786 | pubmed:meshHeading | pubmed-meshheading:16763786... | lld:pubmed |
| pubmed-article:16763786 | pubmed:meshHeading | pubmed-meshheading:16763786... | lld:pubmed |
| pubmed-article:16763786 | pubmed:meshHeading | pubmed-meshheading:16763786... | lld:pubmed |
| pubmed-article:16763786 | pubmed:meshHeading | pubmed-meshheading:16763786... | lld:pubmed |
| pubmed-article:16763786 | pubmed:meshHeading | pubmed-meshheading:16763786... | lld:pubmed |
| pubmed-article:16763786 | pubmed:meshHeading | pubmed-meshheading:16763786... | lld:pubmed |
| pubmed-article:16763786 | pubmed:meshHeading | pubmed-meshheading:16763786... | lld:pubmed |
| pubmed-article:16763786 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16763786 | pubmed:articleTitle | Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies. | lld:pubmed |
| pubmed-article:16763786 | pubmed:affiliation | Department of Medicine, Institut Gustave-Roussy, Villejuif. | lld:pubmed |
| pubmed-article:16763786 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16763786 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:16763786 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16763786 | lld:pubmed |
